This trial is testing a new drug, ONC-392, as a possible treatment for advanced or metastatic solid tumors and non-small cell lung cancers. The trial will test different doses of the drug to see what is safe and what works best. The trial will also test ONC-392 in combination with another drug, pembrolizumab.
4 Primary · 5 Secondary · Reporting Duration: 1 year
468 Total Participants · 3 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: